301-15-5

Basic information

• Product Name: SYNTHALIN SULFATE
• Synonyms: 1,1’-decamethylenedi-guanidindihydrochloride;anticoman;decanedi-guanidindihydrochloride;decanediguanidinedihydrochloride;n,n’’’-1,10-decanediylbis-guanidindihydrochloride;riddobetes;N,N'-1,10-DECANEDIYLBISGUANIDINE SULFATE;N,N'-1,10-DECANEDIYLBIS(GUANIDINE) H2SO4
• CAS NO: 301-15-5
• Molecular Formula: C₁₂H₂₈N₆*2ClH
• Molecular Weight: 354.47
• EINECS: 206-112-8
• Mol File: 301-15-5.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 462.2°Cat760mmHg
• Flash Point: 233.3°C
• Appearance: /
• Density: 1.15g/cm³
• Storage Temp.: Store at RT
• CAS DataBase Reference: SYNTHALIN SULFATE(CAS DataBase Reference)
• NIST Chemistry Reference: SYNTHALIN SULFATE(301-15-5)
• EPA Substance Registry System: SYNTHALIN SULFATE(301-15-5)

Safety Data

• Hazardous Substances Data: 301-15-5(Hazardous Substances Data)

Usage

Definition

ChEBI: A hydrochloride resulting from the reaction of decamethylenediguanidine with 2 mol eq. of hydrogen chloride.

Biological Activity

An effective non-competitive NMDA receptor antagonist in vivo and in vitro ; may bind to more than one site, one of which is the polyamine site.

Upstream product

• 1598406-60-0 1,10-bis[(3-amino-1,2,4-oxadiazol-5-one)-4-yl]decane 
• 1598406-58-6 decyl-1,10-diethylcyanocarbamate 
• 2188-10-5 decyl-1,10-dicyanamide 
• 646-25-3 diaminodecane 

Relevant articles and documents

Development of the first oral bioprecursors of bisalkylguanidine antimalarial drugs

Plasmodium falciparum is responsible of the most severe form of malaria, and new targets and novel chemotherapeutic scaffolds are needed to fight emerging multidrug-resistant strains of this parasite. Bis-alkylguanidines have been designed to mimic choline, resulting in the inhibition of plasmodial de novo phosphatidylcholine biosynthesis. Despite potent in vitro antiplasmodial and in vivo antimalarial activities, a major drawback of these compounds for further clinical development is their low oral bioavailability. To solve this issue, various modulations were performed on bis-alkylguanidines. The introduction of N-disubstituents on the guanidino motif improved both in vitro and in vivo activities. On the other hand, in vivo pharmacological evaluation in a mouse model showed that the N-hydroxylated derivatives constitute the first oral bioprecursors in bis-alkylguanidine series. This study paves the way for bis-alkylguanidine-based oral antimalarial agents targeting plasmodial phospholipid metabolism.